Slingshot Biosciences Appoints Glenn Bilawsky as CEO to Lead Strategic Expansion across Clinical Trial and Diagnostic Markets
This transition is a strategic inflection point as Slingshot scales to meet rising global demand for cell mimics as standardized, reliable alternatives to biological controls. The widespread adoption of its TruCytes™ and SpectraComp ® products across research, clinical trials, diagnostics, and cell therapy applications is driving the company to expand its commercial footprint, industry partnerships, and advance regulatory-grade solutions.
'Slingshot is transforming how scientists in diagnostic, and therapeutic research and development access and apply cellular controls,' said Glenn Bilawsky, CEO. 'Jeff has built a remarkable company rooted in scientific excellence. I'm excited to build on that foundation—scaling the commercial team and focusing our portfolio to ensure our solutions maintain their position as the gold standard of cell-based controls used in regulated and research workflows.'
Bilawsky brings decades of success and leadership in scaling life science, contract research, and analytical laboratory service companies focused on biomarker development. His appointment will accelerate Slingshot's momentum and the achievement of its mission to replace traditional biological reference materials with scalable, customizable and cost-effective cell mimic controls.
Dr. Kim, who invented and led the development of Slingshot's core technologies, emphasized continuity in the company's mission: 'I'm proud of how far Slingshot has come. Glenn brings a remarkable track record of success and his leadership will unlock our next phase of growth. I am committed to the continued support of the company and look forward to working with Glenn in this next phase of the business.'
About Slingshot Biosciences
Slingshot Biosciences develops cell mimics for a range of applications in diagnostics and therapeutics. Slingshot leverages advances in distributed manufacturing, engineering, and polymer chemistry to provide an industry-first, off-the-shelf customizable solution for cell-like reagents that are stable and targeted toward a range of indications and markets. www.slingshotbio.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
Accord Announces Amendment to its Banking Facility
TORONTO--(BUSINESS WIRE)--Accord Financial Corp. (TSX – ACD) today announced it has amended its senior secured revolving credit facility (the 'Credit Facility'), extending the maturity date to December 15, 2025. This amendment follows two recent short-term extensions: the first announced on July 25, 2025, and the second on August 8, 2025, which extended the maturity date to August 15, 2025. Under the new terms, the total commitment will be reduced from $260 million to $200 million. The amendment also incorporates milestones tied to potential asset sales (with net proceeds to be used to repay bank indebtedness), increases the interest rate on drawn amounts by 1.00%, and updates certain financial covenants. 'While the amendment includes higher pricing and a reduced commitment, the extension provides time for the Company to continue to actively pursue a broad range of strategic initiatives to address the Company's maturing debt obligations (totalling $217.6 million as at June 30, 2025 and coming due by January 31, 2026) and maximize shareholder value,' said Mr. Hitzig. 'These include potential divestitures of portfolio assets or business units, as well as other financing alternatives. The Company continues to work closely with its financial advisors, but there is no assurance that these initiatives will yield a successful result. While we focus on these initiatives, profitable operating performance and growth will continue to be a challenge.' The Company does not plan to provide further updates on its strategic initiatives unless material developments emerge. A Material Change Report and the amended Credit Facility agreement will be filed on SEDAR+ at About Accord Financial Corp. Accord Financial is one of North America's most dynamic commercial finance companies providing fast, versatile financing solutions including asset-based lending, factoring, inventory finance, equipment finance (in Canada), trade finance and film/media finance. By leveraging our unique combination of deep experience and independent thinking, we craft winning financial solutions for small and medium-sized businesses, simply delivered, so our clients can thrive. For further information please visit or contact: Forward-Looking Statements This news release contains certain "forward-looking statements" and certain "forward-looking information" as defined under applicable Canadian securities laws. Forward-looking statements can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue", "plans" or similar terminology. Forward-looking statements in this news release include, but are not limited to, statements, management's beliefs, expectations or intentions regarding the financial position of the Company and the ability of the Company to repay or refinance its outstanding debt obligations. Forward-looking statements are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements are subject to various risks and uncertainties including the Company's overall liquidity and capital resource position and its ability to repay its debt obligations when due and those risks identified in the Accord's periodic filings with Canadian securities regulators. If any or all of the Company's outstanding debt obligations are not renewed or replaced upon expiration of their terms, and if the Company is unsuccessful in its ability to generate additional capital from sales of portfolio assets and/or business units and additional alternative financing arrangements to repay same on terms acceptable to the Company, or at all, the Company may not be able to continue to finance its operations and operate as a going concern. See Accord's most recent annual information form and most recent management's discussion and analysis of results of operations and financial condition for a detailed discussion of the risk factors affecting Accord. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.
Business Wire
3 hours ago
- Business Wire
Elizabeth Walker Wadsworth, MD, MSCR, Joins Advanced ENT & Allergy, Bringing Expert ENT and Inspire® Sleep Apnea Care to Atlanta
ATLANTA--(BUSINESS WIRE)--Advanced ENT & Allergy is pleased to welcome Elizabeth Walker Wadsworth, MD, MSCR, a highly trained otolaryngologist from Atlanta's Buckhead community. Dr. Wadsworth provides comprehensive care for adults and children with conditions of the ear, nose, and throat, with special expertise in chronic sinusitis, hearing loss, and innovative treatments for sleep apnea, including the Inspire® implantable device. Dr. Wadsworth returning to Atlanta to treat the community she grew up in. Share Dr. Wadsworth earned her medical degree from Emory University School of Medicine and completed her residency in Otolaryngology–Head and Neck Surgery at the Medical University of South Carolina (MUSC), a top-ten residency program nationally. She is board-eligible in otolaryngology and is committed to delivering individualized, evidence-based care that improves breathing, hearing, and sleep health. 'As someone who grew up in Buckhead, it's a privilege to return home to care for patients in the city that shaped me,' said Dr. Wadsworth. 'Whether I'm helping a patient breathe easier, hear better, or finally sleep soundly, I strive to combine the best available treatments with genuine compassion and clear communication.' During her residency, Dr. Wadsworth gained extensive experience in advanced sinus surgery, ENT allergy management, pediatric and adult hearing loss, and the surgical implantation of the Inspire® upper airway stimulation system — an effective alternative for patients with obstructive sleep apnea who cannot tolerate CPAP therapy. Dr. Wadsworth is now accepting new patients at Advanced ENT & Allergy, located at 960 Johnson Ferry Rd NE, Suite 200, Atlanta, GA 30342. About Advanced ENT & Allergy Advanced ENT & Allergy is a leading provider of comprehensive ear, nose, and throat care in the Atlanta area. Our board-certified providers emphasize advanced treatment options, patient education, and individualized service in a welcoming, service-oriented environment.
Business Wire
4 hours ago
- Business Wire
LifeX Term Income ETFs Announce the Closure and Liquidation of Two Exchange-Traded Funds
NEW YORK--(BUSINESS WIRE)--LifeX Term Income ETFs ('LifeX') has announced that it will close and liquidate two exchange-traded funds to simplify its fund lineup. LifeX will be liquidating the LifeX 2040 Term Income ETF and LifeX 2045 Term Income ETF (together, the 'Liquidating ETFs') (such transactions, the 'Liquidations'). The Liquidations are expected to take place on or about August 22, 2025 (the 'Liquidation Date'). August 20, 2025 is expected to be the last full day of trading for the Liquidating ETFs' shares. The Liquidating ETFs expect to operate pursuant to their stated investment strategies through the Liquidation Date. While the investment objective of each Liquidating ETF is to provide monthly distributions through the year in such Liquidating ETF's name, the Liquidating ETFs will instead seek to liquidate and distribute their remaining assets to shareholders promptly following the Liquidation Date. In each case, the liquidation proceeds are expected to be distributed promptly following the Liquidation Date in full redemption of each shareholder's shares of the Liquidating ETFs. For additional information about the liquidations, shareholders of the Liquidating ETFs may call 855-609-3680. About LifeX Term Income ETFs LifeX Term Income ETFs are designed to provide reliable monthly distributions consisting of income and principal through the end of a calendar year specified in the ETF's prospectus. To learn more, please visit Risk Disclosures Investing involves risk. Principal loss is possible. Investors should consider the investment objectives, risks, charges, and expenses carefully before investing. For a prospectus with this and other information about the fund, please visit or call 855-609-3680. Please read the prospectus carefully before investing. Distributed by Foreside Financial Services, LLC.
